NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$159.19 +2.62 (+1.67 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$156.57
Today's Range$155.76 - $160.28
52-Week Range$125.50 - $178.25
Volume2.17 million shs
Average Volume1.68 million shs
Market Capitalization$40.17 billion
P/E Ratio198.99
Dividend YieldN/A
Beta1.43
Vertex Pharmaceuticals logoVertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100

Debt

Debt-to-Equity Ratio0.01
Current Ratio3.68
Quick Ratio3.53

Price-To-Earnings

Trailing P/E Ratio198.99
Forward P/E Ratio81.64
P/E Growth1.92

Sales & Book Value

Annual Sales$2.49 billion
Price / Sales16.30
Cash Flow$1.0591 per share
Price / Cash150.31
Book Value$8.08 per share
Price / Book19.70

Profitability

EPS (Most Recent Fiscal Year)$0.80
Net Income$263.48 million
Net Margins9.36%
Return on Equity15.28%
Return on Assets8.90%

Miscellaneous

Employees2,300
Outstanding Shares254,830,000

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals declared that its board has approved a share repurchase program on Thursday, February 1st 2018, which permits the company to buyback $500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its earnings results on Thursday, April, 26th. The pharmaceutical company reported $0.76 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.63 by $0.13. The pharmaceutical company had revenue of $641 million for the quarter, compared to analyst estimates of $626.05 million. Vertex Pharmaceuticals had a return on equity of 15.28% and a net margin of 9.36%. The business's revenue for the quarter was down 10.2% on a year-over-year basis. During the same period last year, the firm posted $0.99 EPS. View Vertex Pharmaceuticals' Earnings History.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Vertex Pharmaceuticals.

What price target have analysts set for VRTX?

26 equities research analysts have issued 12-month target prices for Vertex Pharmaceuticals' stock. Their forecasts range from $98.00 to $211.00. On average, they expect Vertex Pharmaceuticals' stock price to reach $183.8077 in the next twelve months. View Analyst Ratings for Vertex Pharmaceuticals.

What are Wall Street analysts saying about Vertex Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
  • 1. Maxim Group analysts commented, "Vertex reported 1Q18 with revenue of $641M, beating consensus of $622M. Kalydeco revenue of $250M beat consensus of $230M, Orkambi/Symdeko revenue of $388M (Orkambi $354M, Symdeko $34M) beat consensus of $374M. Overall, total CF revenue was $638M, a y/y increase of 33%. Non-GAAP operating expenses were $360M and Non-GAAP EPS of $0.76 beat consensus $0.62. Vertex ended the period with $2.5B in cash." (4/27/2018)
  • 2. According to Zacks Investment Research, "Vertex’ efforts to get its two CF drugs — Kalydeco & Orkambi — approved for additional indications are encouraging. In 2017, positive data read-outs and regulatory approvals have increased the eligible patient population for Kalydeco & Orkambi, which is driving sales growth. Vertex’s CF pipeline is also quite strong with a broad portfolio of next-generation CF correctors. Investor focus is on the triple combination CF regimens, which are crucial for long-term growth, as they have the potential to treat up to 90% of CF patients. The FDA approval of the third CF medicine, Symdeko, in February was encouraging. The stock has outperformed the industry this year so far. However, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. Estimate movement has been mixed ahead of Q1 earnings release. Vertex has a positive record of earnings surprises in the recent quarters." (4/20/2018)
  • 3. HC Wainwright analysts commented, "Halts Triple Combination Trials in France as a Protest in Pricing Negotiations What’s new? We have recently learned via a twitter comment and associated article (http://bit.ly/2Bp7vL7) that Vertex has decided to discontinue the Phase 3 trials of its triple combination therapy for cystic fibrosis (CF) in France. During the Vertex 4Q earnings call, management identified the two second-generation correctors that would be added to the combination of tezacaftor/ivacaftor to formulate the triple combination. It appears that these trials will continue in the US and other parts of Europe but will now be excluding France due to an inability to reach reimbursement agreement with the French authorities for Orkambi. As mentioned in the article, this is a disappointment to the French CF patients that have been consistent participants in numerous trials to date and were eagerly awaiting more rapid access to what could be the most effective modulator treatment yet for CF." (2/13/2018)

Who are some of Vertex Pharmaceuticals' key competitors?

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the folowing people:
  • Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 62)
  • Mr. Thomas Graney, CFO & Sr. VP (Age 53)
  • Mr. Ian F. Smith, Exec. VP & COO (Age 52)
  • Dr. David M. Altshuler, Chief Scientific Officer & Exec. VP of Global Research (Age 53)
  • Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 43)

Has Vertex Pharmaceuticals been receiving favorable news coverage?

Headlines about VRTX stock have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a news impact score of 0.22 on Accern's scale. They also gave media headlines about the pharmaceutical company an impact score of 45.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.80%), Northern Trust Corp (1.10%), Wells Fargo & Company MN (0.79%), Massachusetts Financial Services Co. MA (0.60%), Old Mutual Global Investors UK Ltd. (0.55%) and Amundi Pioneer Asset Management Inc. (0.50%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Margaret G Mcglynn, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Institutional Ownership Trends for Vertex Pharmaceuticals.

Which institutional investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Manning & Napier Group LLC, PointState Capital LP, Franklin Resources Inc., Wells Fargo & Company MN, Swiss National Bank, Caisse DE Depot ET Placement DU Quebec and Guggenheim Capital LLC. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Insider Buying and Selling for Vertex Pharmaceuticals.

Which institutional investors are buying Vertex Pharmaceuticals stock?

VRTX stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Summit Trail Advisors LLC, BlackRock Inc., Royal Bank of Canada, Federated Investors Inc. PA, Westfield Capital Management Co. LP, Green Valley Investors LLC and British Airways Pensions Investment Management Ltd. View Insider Buying and Selling for Vertex Pharmaceuticals.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $159.19.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $40.17 billion and generates $2.49 billion in revenue each year. The pharmaceutical company earns $263.48 million in net income (profit) each year or $0.80 on an earnings per share basis. Vertex Pharmaceuticals employs 2,300 workers across the globe.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]


MarketBeat Community Rating for Vertex Pharmaceuticals (VRTX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,079 (Vote Outperform)
Underperform Votes:  609 (Vote Underperform)
Total Votes:  1,688
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.